Invivyd, Inc. (NASDAQ:IVVD) Shares Bought by State Street Corp

State Street Corp grew its holdings in Invivyd, Inc. (NASDAQ:IVVD) by 3.7% in the 3rd quarter, Holdings Channel.com reports. The fund owned 1,018,640 shares of the company’s stock after buying an additional 35,904 shares during the period. State Street Corp’s holdings in Invivyd were worth $1,039,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Proficio Capital Partners LLC acquired a new stake in Invivyd during the 3rd quarter worth about $27,000. Cubist Systematic Strategies LLC lifted its holdings in shares of Invivyd by 66.1% during the second quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock worth $148,000 after purchasing an additional 53,499 shares during the period. Susquehanna Fundamental Investments LLC purchased a new stake in Invivyd in the second quarter valued at approximately $115,000. Dimension Capital Management LLC increased its holdings in Invivyd by 243.3% in the 2nd quarter. Dimension Capital Management LLC now owns 189,871 shares of the company’s stock worth $209,000 after buying an additional 134,571 shares during the period. Finally, Duquesne Family Office LLC purchased a new position in Invivyd during the 2nd quarter worth approximately $629,000. Hedge funds and other institutional investors own 70.36% of the company’s stock.

Insider Activity at Invivyd

In other Invivyd news, Director Terrance Mcguire sold 150,000 shares of the company’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $0.61, for a total transaction of $91,500.00. Following the completion of the transaction, the director now directly owns 4,538,079 shares in the company, valued at approximately $2,768,228.19. This represents a 3.20 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders sold a total of 816,466 shares of company stock worth $423,214 in the last 90 days. Corporate insiders own 17.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. D. Boral Capital reiterated a “buy” rating and issued a $9.00 price objective on shares of Invivyd in a research note on Thursday, November 21st. HC Wainwright cut their price target on Invivyd from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, November 20th. EF Hutton Acquisition Co. I raised Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. Finally, Morgan Stanley dropped their target price on Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a report on Wednesday, November 20th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $7.89.

Invivyd Stock Performance

Shares of Invivyd stock opened at $0.48 on Friday. The firm has a 50-day simple moving average of $0.70 and a two-hundred day simple moving average of $0.95. Invivyd, Inc. has a fifty-two week low of $0.40 and a fifty-two week high of $5.20. The company has a market cap of $57.42 million, a P/E ratio of -0.24 and a beta of 0.53.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.